Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Warfarin

Known as: 3-Alpha-phenyl-beta-acetylethyl-4-hydroxycoumarin, 3-(.alpha.-Phenyl-.beta.-acetylethyl)-4-hydroxycoumarin, 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- 
A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial… Expand
Highly Cited
2013
Highly Cited
2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of… Expand
  • table 1
  • figure 1
Highly Cited
2013
Highly Cited
2013
BACKGROUND Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2011
Highly Cited
2011
BACKGROUND The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2011
Highly Cited
2011
BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Highly Cited
2009
Highly Cited
2009
BACKGROUND Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is… Expand
  • table 1
  • figure 1
  • table 4
Highly Cited
2009
Highly Cited
2009
To the Editor: Although Connolly et al. (Sept. 17 issue)1 have demonstrated a modest advantage for dabigatran over warfarin in… Expand
  • table 1
Highly Cited
2009
Highly Cited
2009
BACKGROUND The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2009
Highly Cited
2009
BACKGROUND Genetic variability among patients plays an important role in determining the dose of warfarin that should be used… Expand
Highly Cited
2005
Highly Cited
2005
BACKGROUND The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2